Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Makoto, Aoyama

Irini Akritopoulou-Zanze

Stevan Wakefield Djuric

Wilfried Martin Braje

Ana-Lucia Relo

Alan Frank Gasiecki

Jyoti R Patel

Ying Wang

Jason T Brewer

Sean Colm Turner

Frauke Pohlki

Qi Shuai

Kathy A Sarris

Philip R Kym

Anil Vasudevan

Shashank Shekhar

Noel S Wilson

Hongyu H Zhao

Min Zhang

Dennie S Welch

Albert Wayne Kruger

Bhadra Shelat

Jorge Gandarilla

Vijaya J Gracias

Huanqiu Li

Christina M Thompson

Jürgen Dinges

Thomas Dale Penning

Hing L Sham

John K Pratt

Martin Winn

Helmut Mack

Julie M Miyashiro

William H Bunnelle

Zhonghua Pei

Keith W Woods

Adrian Hobson

Marc J Scanio

Paul E Wiedeman

David L Arendsen

Nicole Teusch

Douglas M Kalvin

Biqin C Li

Dawn M George

Lu Wang

Brian D Wakefield

Kresna Hartandi

Melissa J Michmerhuizen

Hana A Kopecka

Steven Lewis Swann, Jr

Daria Darczak

Tom Von Geldern

Benjamin C Lane

Andrew J Long

Jehrod Brenneman

Eric F Johnson

Peter J Kovar

Ethan D Hoff

Anna M Ericsson

Lee Daniel Arnold

Michael Michaelides

Richard W Dixon

Paul Rafferty

James H Holms

Douglas H Steinman

Carol K Wada

Henry Q Zhang

Christine Ann Collins

Zhiren Xia

Ju Gao

Makoto Takeshita

Melanie A Muckey

Margaretha Bakker

Kimba Lee Fischer

Mary Katherin Verzal

Kathleen M Phelan

N St John Moore

Nigel S Moore

Margaretha H M Bakker

Kimba L Ashworth

Hongyu Zhao

Lee D Arnold

Aoyama Makoto

Kimba Fischer

Shashank Shekar

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R, R, R, R, R, R, X, X, X, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R, R, R, R, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Benzodiazepine and pyridodiazepine derivatives

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2 -a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7 -octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2 -a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R, R, R, R, R, R, X, X, X, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Tricyclic pyrazole kinase inhibitors

The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Growing community of inventors

Libertyville, IL, United States of America

Irini Akritopoulou-Zanze